These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34185411)

  • 1. Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer.
    Sakai H; Kawakami H; Teramura T; Onodera Y; Somers E; Furuuchi K; Uenaka T; Kato R; Nakagawa K
    Clin Transl Med; 2021 Jun; 11(6):e454. PubMed ID: 34185411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
    Cheng X; Li J; Tanaka K; Majumder U; Milinichik AZ; Verdi AC; Maddage CJ; Rybinski KA; Fernando S; Fernando D; Kuc M; Furuuchi K; Fang F; Uenaka T; Grasso L; Albone EF
    Mol Cancer Ther; 2018 Dec; 17(12):2665-2675. PubMed ID: 30262588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
    Wen Y; Graybill WS; Previs RA; Hu W; Ivan C; Mangala LS; Zand B; Nick AM; Jennings NB; Dalton HJ; Sehgal V; Ram P; Lee JS; Vivas-Mejia PE; Coleman RL; Sood AK
    Clin Cancer Res; 2015 Jan; 21(2):448-59. PubMed ID: 25416196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models.
    Furuuchi K; Rybinski K; Fulmer J; Moriyama T; Drozdowski B; Soto A; Fernando S; Wilson K; Milinichik A; Dula ML; Tanaka K; Cheng X; Albone E; Uenaka T
    Cancer Sci; 2021 Jun; 112(6):2467-2480. PubMed ID: 33756060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
    Ning G; Zhu Q; Kang W; Lee H; Maher L; Suh YS; Michaud M; Silva M; Kwon JY; Zhang C; Lee C
    BMC Cancer; 2021 Aug; 21(1):923. PubMed ID: 34399705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bmi-1-induced miR-27a and miR-155 promote tumor metastasis and chemoresistance by targeting RKIP in gastric cancer.
    Li Y; Tian Z; Tan Y; Lian G; Chen S; Chen S; Li J; Li X; Huang K; Chen Y
    Mol Cancer; 2020 Jun; 19(1):109. PubMed ID: 32580736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability.
    Li H; Wang C; Lan L; Yan L; Li W; Evans I; Ruiz EJ; Su Q; Zhao G; Wu W; Zhang H; Zhou Z; Hu Z; Chen W; Oliveira JM; Behrens A; Reis RL; Zhang C
    Cell Mol Life Sci; 2022 Feb; 79(3):135. PubMed ID: 35179655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway.
    Han Y; Song C; Wang J; Tang H; Peng Z; Lu S
    Mol Carcinog; 2018 Jun; 57(6):722-734. PubMed ID: 29436749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
    Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
    Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 is a useful prognostic biomarker for resectable gastric cancer.
    Ye Y; Li X; Yang J; Miao S; Wang S; Chen Y; Xia X; Wu X; Zhang J; Zhou Y; He S; Tan Y; Qiang F; Li G; Røe OD; Zhou J
    Cancer Sci; 2013 May; 104(5):590-8. PubMed ID: 23347235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of nuclear-enriched abundant transcript 1 confers oxaliplatin resistance to gastric cancer.
    Li Y; Peng C; Fang C; Huang K
    Cell Biol Int; 2020 Feb; 44(2):446-455. PubMed ID: 31617275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peiminine serves as an adriamycin chemosensitizer in gastric cancer by modulating the EGFR/FAK pathway.
    Tang Q; Wang Y; Ma L; Ding M; Li T; Nie Y; Gu Z
    Oncol Rep; 2018 Mar; 39(3):1299-1305. PubMed ID: 29328433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer.
    Cao Y; Wang J; Tian H; Fu GH
    J Exp Clin Cancer Res; 2020 Jun; 39(1):119. PubMed ID: 32576206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
    Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
    Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated HIF1α of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer.
    Yu S; Li Q; Yu Y; Cui Y; Li W; Liu T; Liu F
    Cancer Immunol Immunother; 2020 Oct; 69(10):1973-1987. PubMed ID: 32388677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2.
    Shuai Y; Ma Z; Liu W; Yu T; Yan C; Jiang H; Tian S; Xu T; Shu Y
    Mol Cancer; 2020 Jan; 19(1):6. PubMed ID: 31924214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers.
    Li X; Zhou S; Abrahams CL; Krimm S; Smith J; Bajjuri K; Stephenson HT; Henningsen R; Hanson J; Heibeck TH; Calarese D; Tran C; Yin G; Stafford RL; Yam AY; Kline T; De Almeida VI; Sato AK; Lupher M; Bedard K; Hallam TJ
    Mol Cancer Ther; 2023 Feb; 22(2):155-167. PubMed ID: 36459691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers.
    Zhang ZZ; Yu WX; Zheng M; Liao XH; Wang JC; Yang DY; Lu WX; Wang L; Zhang S; Liu HK; Zhou XZ; Lu KP
    Mol Cancer Ther; 2020 Mar; 19(3):906-919. PubMed ID: 31879364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circular RNA circCCDC9 acts as a miR-6792-3p sponge to suppress the progression of gastric cancer through regulating CAV1 expression.
    Luo Z; Rong Z; Zhang J; Zhu Z; Yu Z; Li T; Fu Z; Qiu Z; Huang C
    Mol Cancer; 2020 May; 19(1):86. PubMed ID: 32386516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-135a promotes gastric cancer progression and resistance to oxaliplatin.
    Yan LH; Chen ZN; Li-Li ; Chen J; Wei WE; Mo XW; Qin YZ; Lin Y; Chen JS
    Oncotarget; 2016 Oct; 7(43):70699-70714. PubMed ID: 27683111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.